GuruFocus ranks the company's profitability 7 out of 10 on the back of operating margins that have expanded over the past five years and are outperforming over 77% of global competitors.The New Brunswick, New Jersey-based company said this week that it accelerated its Phase 1/2a study for its Covid-19 vaccine candidate from its previous date in September to late July.